Cargando…
Home treatment of haemarthrosis with recombinant activated factor VII in patients with haemophilia A or B and inhibitors: experience from developing countries
Home therapy for uncomplicated mild/moderate bleeding can decrease healthcare burden, promote self-esteem, reduce complications, and provide near-normal quality of life. To evaluate recombinant activated factor VII (rFVIIa) as home therapy for joint bleeds in Algeria, Morocco, Oman, Saudi Arabia, an...
Autores principales: | , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams And Wilkins
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5312720/ https://www.ncbi.nlm.nih.gov/pubmed/27100303 http://dx.doi.org/10.1097/MBC.0000000000000564 |
_version_ | 1782508246067576832 |
---|---|
author | Bensadok, Meriem Almomen, Abdulkareem Alzoebie, Azzam Benchikh el Fegoun, Soraya Wali, Yasser Hamzy, Fati Mehalhal, Nemra Gaid Grifi, Fatiha Hamdi, Selma Mesli, Naima Owaidah, Tarek Saad, Hossam Ali Mansour, Nouredine Sidi Touhami, Hadj |
author_facet | Bensadok, Meriem Almomen, Abdulkareem Alzoebie, Azzam Benchikh el Fegoun, Soraya Wali, Yasser Hamzy, Fati Mehalhal, Nemra Gaid Grifi, Fatiha Hamdi, Selma Mesli, Naima Owaidah, Tarek Saad, Hossam Ali Mansour, Nouredine Sidi Touhami, Hadj |
author_sort | Bensadok, Meriem |
collection | PubMed |
description | Home therapy for uncomplicated mild/moderate bleeding can decrease healthcare burden, promote self-esteem, reduce complications, and provide near-normal quality of life. To evaluate recombinant activated factor VII (rFVIIa) as home therapy for joint bleeds in Algeria, Morocco, Oman, Saudi Arabia, and United Arab Emirates. Twenty-seven patients aged more than 2 years with congenital haemophilia and inhibitors were monitored for up to 8 months after a first haemarthrosis episode treated with rFVIIa. Assessments were made by patients/caregivers with a standardized diary. The main measures included home-managed bleeds, haemostasis, and pain relief within 9 h after first injection. Additional analyses included convenience, time to pain resolution, and doses given within 48 h. Of 132 bleeds, 84 (63.6%) were managed at home. Of these, successful haemostasis (partial or complete) was achieved at 9 h in 87.8%, with pain relief for 84.0%. For all treatment settings, successful haemostasis at 9 h was achieved for 86.3% of bleeds, with pain relief achieved for 74.8% of bleeds. Higher initial dosing was associated with fewer injections. Median time to complete haemostasis was 48 h (spontaneous bleeds) and 24 h (traumatic bleeds). Median time to complete pain relief was 24 h for both bleed types. Satisfaction with treatment was high. No safety concerns were reported. Results from this observational study agree with previous data on the safety and efficacy of home treatment with rFVIIa and will help to increase awareness and aggregate experience, fostering confidence in home management of haemophilia patients with inhibitors in developing countries. |
format | Online Article Text |
id | pubmed-5312720 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | Lippincott Williams And Wilkins |
record_format | MEDLINE/PubMed |
spelling | pubmed-53127202017-03-02 Home treatment of haemarthrosis with recombinant activated factor VII in patients with haemophilia A or B and inhibitors: experience from developing countries Bensadok, Meriem Almomen, Abdulkareem Alzoebie, Azzam Benchikh el Fegoun, Soraya Wali, Yasser Hamzy, Fati Mehalhal, Nemra Gaid Grifi, Fatiha Hamdi, Selma Mesli, Naima Owaidah, Tarek Saad, Hossam Ali Mansour, Nouredine Sidi Touhami, Hadj Blood Coagul Fibrinolysis Original Articles Home therapy for uncomplicated mild/moderate bleeding can decrease healthcare burden, promote self-esteem, reduce complications, and provide near-normal quality of life. To evaluate recombinant activated factor VII (rFVIIa) as home therapy for joint bleeds in Algeria, Morocco, Oman, Saudi Arabia, and United Arab Emirates. Twenty-seven patients aged more than 2 years with congenital haemophilia and inhibitors were monitored for up to 8 months after a first haemarthrosis episode treated with rFVIIa. Assessments were made by patients/caregivers with a standardized diary. The main measures included home-managed bleeds, haemostasis, and pain relief within 9 h after first injection. Additional analyses included convenience, time to pain resolution, and doses given within 48 h. Of 132 bleeds, 84 (63.6%) were managed at home. Of these, successful haemostasis (partial or complete) was achieved at 9 h in 87.8%, with pain relief for 84.0%. For all treatment settings, successful haemostasis at 9 h was achieved for 86.3% of bleeds, with pain relief achieved for 74.8% of bleeds. Higher initial dosing was associated with fewer injections. Median time to complete haemostasis was 48 h (spontaneous bleeds) and 24 h (traumatic bleeds). Median time to complete pain relief was 24 h for both bleed types. Satisfaction with treatment was high. No safety concerns were reported. Results from this observational study agree with previous data on the safety and efficacy of home treatment with rFVIIa and will help to increase awareness and aggregate experience, fostering confidence in home management of haemophilia patients with inhibitors in developing countries. Lippincott Williams And Wilkins 2017-03 2016-04-28 /pmc/articles/PMC5312720/ /pubmed/27100303 http://dx.doi.org/10.1097/MBC.0000000000000564 Text en Copyright © 2017 The Author(s). Published by Wolters Kluwer Health, Inc. http://creativecommons.org/licenses/by-nc-nd/4.0 This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal. http://creativecommons.org/licenses/by-nc-nd/4.0 |
spellingShingle | Original Articles Bensadok, Meriem Almomen, Abdulkareem Alzoebie, Azzam Benchikh el Fegoun, Soraya Wali, Yasser Hamzy, Fati Mehalhal, Nemra Gaid Grifi, Fatiha Hamdi, Selma Mesli, Naima Owaidah, Tarek Saad, Hossam Ali Mansour, Nouredine Sidi Touhami, Hadj Home treatment of haemarthrosis with recombinant activated factor VII in patients with haemophilia A or B and inhibitors: experience from developing countries |
title | Home treatment of haemarthrosis with recombinant activated factor VII in patients with haemophilia A or B and inhibitors: experience from developing countries |
title_full | Home treatment of haemarthrosis with recombinant activated factor VII in patients with haemophilia A or B and inhibitors: experience from developing countries |
title_fullStr | Home treatment of haemarthrosis with recombinant activated factor VII in patients with haemophilia A or B and inhibitors: experience from developing countries |
title_full_unstemmed | Home treatment of haemarthrosis with recombinant activated factor VII in patients with haemophilia A or B and inhibitors: experience from developing countries |
title_short | Home treatment of haemarthrosis with recombinant activated factor VII in patients with haemophilia A or B and inhibitors: experience from developing countries |
title_sort | home treatment of haemarthrosis with recombinant activated factor vii in patients with haemophilia a or b and inhibitors: experience from developing countries |
topic | Original Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5312720/ https://www.ncbi.nlm.nih.gov/pubmed/27100303 http://dx.doi.org/10.1097/MBC.0000000000000564 |
work_keys_str_mv | AT bensadokmeriem hometreatmentofhaemarthrosiswithrecombinantactivatedfactorviiinpatientswithhaemophiliaaorbandinhibitorsexperiencefromdevelopingcountries AT almomenabdulkareem hometreatmentofhaemarthrosiswithrecombinantactivatedfactorviiinpatientswithhaemophiliaaorbandinhibitorsexperiencefromdevelopingcountries AT alzoebieazzam hometreatmentofhaemarthrosiswithrecombinantactivatedfactorviiinpatientswithhaemophiliaaorbandinhibitorsexperiencefromdevelopingcountries AT benchikhelfegounsoraya hometreatmentofhaemarthrosiswithrecombinantactivatedfactorviiinpatientswithhaemophiliaaorbandinhibitorsexperiencefromdevelopingcountries AT waliyasser hometreatmentofhaemarthrosiswithrecombinantactivatedfactorviiinpatientswithhaemophiliaaorbandinhibitorsexperiencefromdevelopingcountries AT hamzyfati hometreatmentofhaemarthrosiswithrecombinantactivatedfactorviiinpatientswithhaemophiliaaorbandinhibitorsexperiencefromdevelopingcountries AT mehalhalnemragaid hometreatmentofhaemarthrosiswithrecombinantactivatedfactorviiinpatientswithhaemophiliaaorbandinhibitorsexperiencefromdevelopingcountries AT grififatiha hometreatmentofhaemarthrosiswithrecombinantactivatedfactorviiinpatientswithhaemophiliaaorbandinhibitorsexperiencefromdevelopingcountries AT hamdiselma hometreatmentofhaemarthrosiswithrecombinantactivatedfactorviiinpatientswithhaemophiliaaorbandinhibitorsexperiencefromdevelopingcountries AT meslinaima hometreatmentofhaemarthrosiswithrecombinantactivatedfactorviiinpatientswithhaemophiliaaorbandinhibitorsexperiencefromdevelopingcountries AT owaidahtarek hometreatmentofhaemarthrosiswithrecombinantactivatedfactorviiinpatientswithhaemophiliaaorbandinhibitorsexperiencefromdevelopingcountries AT saadhossamali hometreatmentofhaemarthrosiswithrecombinantactivatedfactorviiinpatientswithhaemophiliaaorbandinhibitorsexperiencefromdevelopingcountries AT mansournouredinesidi hometreatmentofhaemarthrosiswithrecombinantactivatedfactorviiinpatientswithhaemophiliaaorbandinhibitorsexperiencefromdevelopingcountries AT touhamihadj hometreatmentofhaemarthrosiswithrecombinantactivatedfactorviiinpatientswithhaemophiliaaorbandinhibitorsexperiencefromdevelopingcountries |